Mylan Health has lost its challenge to a ruling that invalidated three patents related to its blockbuster cholesterol drug Lipidil, despite the appeals court finding the primary judge had erred by ruling that proof of intention was required for Swiss-style claims.
Drug manufacturer Janssen wants to expand its high stakes case against Juno Pharmaceuticals over its HIV drug Prezista, alleging Juno’s plans to launch a generic version of the drug threaten another one of its patents.
Ariosa Diagnostics is fighting to revoke a patent for noninvasive prenatal test owned by Sequenom, arguing it merely describes how to extract “incorporeal” genetic information that is naturally found within the DNA of an unborn foetus.
Drug maker Janssen has fired off a lawsuit against Juno Pharmaceuticals for allegedly threatening to infringe a patent for its HIV drug Prezista with a generic version of the drug, one year after fending off generic competition from a different drug maker.
The Brisbane-based burger chain at the centre of a trademark stoush with buffet bar pioneer Sizzler has agreed to refrain from its allegedly infringing trade mark use until the case is decided.
Casual dining pioneer Sizzler has served up a trade mark lawsuit over an eponymous burger sold by a Brisbane-based burger chain and marketed as an “ode to the cultural icon”.
Coffee capsule machine manufacturer Caffitaly has suffered a significant loss in its intellectual property case against a rival, with the Federal Court dismissing its infringement claims and revoking three of its patents in a single shot.
A trade mark infringement lawsuit filed by the former CEO of the Australian Bar Association was not properly brought as a class action on behalf of member barristers, a judge has found.
The Full Federal Court has rejected a patent application for a digital advertising system by e-commerce firm Rokt in a test case by IP Australia that comes as a blow to the patentability of computer software in Australia.
A court has dismissed a claim by the Australian Government for $325 million against pharmaceutical companies Sanofi and Bristol-Myers Squibb allegedly owed for excess subsidies it paid for blood-thinner Plavix as a result of an interlocutory injunction blocking a generic version of the blockbuster drug.